<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170207032439N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-12-14</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluating the effect of consumption of synbiotic pomegranate juice in women with Poly Cystic Ovarian Syndrome</public_title>
      <acronym>synbiotic pomegranate juice</acronym>
      <scientific_title>Evaluating the effect of consumption of synbiotic pomegranate juice on lipid profile, anthropometric markesrs and quality of life in women with Poly Cystic Ovarian Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>92</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/25273</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: We randomly assigned patients to a ratio of 1: 1: 1: 1 to 4 groups.&#13;
A scholar who did not have any clinical intervention, randomly classified the patinets by random blocking software with a fixed block size of 4 in randomized groups.&#13;
In order to blind patients, the drinks in all groups are identical in appearance, color and taste.&#13;
The drinks are coded differently in each group and then will be given to the scholar to blinde him.&#13;
Finally, the data and information are also given to the analyzer with the special code for each group in order to blinde analayzer, Randomization description: Balanced Block Randomization, Blinding description: Beverages in all groups are identical in terms of appearance, color and taste.Drinks with different codes in each group will be given to blindness to the researcher  and Finally, the data and information are also given to the statistics specialist by the special code for each group to make a blindfold for the statistics specialist.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Poly cystic ovarian syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Patients who receive 2 liters of synbiotic pomegranate juice each week, which consists of pomegranate juice, enriched with inulin and lactobacillus, in the form of disposable bottles for 8 weeks. Intervention 2: Patients who receive 2 liters of  pomegranate juice each week, in the form of disposable bottles for 8 weeks. Intervention 3: Patients who receive 2 liters of synbiotic  juice each week, which consists of placebo, enriched with inulin and lactobacillus, in the form of disposable bottles for 8 weeks. Intervention 4: Patients who receive 2 liters of placebo juice each week, which consists of pomegranate flavore, in the form of disposable bottles for 8 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about the consequences is shared

When:
Since 2019

To whom:
Academic researchers

Conditions:
To evaluate the statistical analysis

Where to obtain:
Reza Barati
reza93barati@gmail.com

How to obtain:
Maximum one week after receiving the application

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zahra Esmaeilinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8876115956</zip>
        <telephone>+98 71 3225 6271</telephone>
        <email>sahar.esn8@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Esmaeilinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8876115956</zip>
        <telephone>+98 71 3225 6271</telephone>
        <email>sahar.esnj8@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria  PCOS could be diagnosed, after the exclusion of related disorders, by two of the following three features:  Oligomenorrhea (Less Than 6-9 Menses per Year) or amenorrhea (no vaginal bleeding for at least 6 months);  Clinical findings: Increased blood androgen levels (hirsutism higher than 7 or acne), or increased blood testosterone levels (testosterone levels above 2 nmol / l);  Polycystic ovaries in ultrasound (presence of 12 or more cysts with a diameter of 9.2 mm inside one or both ovaries or the size of the ovary 10 cm 3 or more); BMI&gt;18; Having permission the doctor and informed consent to participate in the study</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>48 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Other medical conditions related to excess androgens such as increased blood prolactin; nonclassical congenital adrenal hyperplasia; Cushing's syndrome; androgen-producing tumors and acromegaly wemon with severe diseases of the stomach, intestines, heart; kidne; liver; lung; chronic; autoimmune; inflammatory and AIDS; Patients undergoing chemotherapy; smokers; Lactating women Patients treated with corticosteroids and antibiotics; The use of supplements of vitamins; minerals and antioxidants; Those taking hormone pills or supplements; Patients using insulin to treat diabetes; Patients with a special diet; Patients with specific exercise program</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Patients who receive 2 liters of synbiotic pomegranate juice each week, which consists of pomegranate juice, enriched with inulin and lactobacillus, in the form of disposable bottles for 8 weeks.</i_keyword>
      <i_keyword>Patients who receive 2 liters of  pomegranate juice each week, in the form of disposable bottles for 8 weeks.</i_keyword>
      <i_keyword>Patients who receive 2 liters of synbiotic  juice each week, which consists of placebo, enriched with inulin and lactobacillus, in the form of disposable bottles for 8 weeks.</i_keyword>
      <i_keyword>Patients who receive 2 liters of placebo juice each week, which consists of pomegranate flavore, in the form of disposable bottles for 8 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Total Cholestrol. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.</prim_outcome>
      <prim_outcome>HDL-C. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.</prim_outcome>
      <prim_outcome>LDL-C. Timepoint: Before and 2 month after intervention. Method of measurement: Autoanalyzer.</prim_outcome>
      <prim_outcome>Health-related quality of life in polycystic ovary syndrome patients. Timepoint: Before and 2 month after intervention. Method of measurement: Questionaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Mensturation cycle. Timepoint: Before and 2 month after intervention. Method of measurement: Questionare.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2010-09-23</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Razi street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
